Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin vs amoxicillin/clavulanate + clarithromycin for acute bacterial rhinosinusitis
2005-002779-34Phase 4Terminated
- Sponsor
- Bayer
- Start
- Mar 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of moxifloxacin in Acute bacterial rhinosinusitis (ABRS) (2 arms), sponsored by Bayer. Started Mar 2006; status: terminated.
02
Drugs
moxifloxacin
03
Conditions
Acute bacterial rhinosinusitis (ABRS)
Beyond the preview
Go deeper on 2005-002779-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002779-34.